Data as of Aug 25, 2026 · Based on 3,181,687 AI responses across 10,525 prompts · See how Parse measures this
Clickotineclicktherapeutics.comClick Therapeutics develops personalized data-driven digital therapeutics for chronic conditions using the CLICK Neurobehavioral Intervention Platform, including Clickotine, a digital program for smoking cessation. In a fully remote 8-week study with 416 participants, Clickotine achieved high engagement (average 100.5 app openings and 130.4 substantive interactions) and 45.2% stopped smoking for at least 7 days, with 26.2% reaching 30-day sustained abstinence. A large randomized trial is planned, and the commercial Clickotine version offered through Magellan Health provides live coaching and nicotine replacement therapy, with the company also pursuing digital interventions for other addictions and chronic conditions.
Click TherapeuticsClickotineParse Score
Sources
clicktherapeutics.com shapes more of what AI says about Clickotine than any other source, at 43% of its citations.
pmc.ncbi.nlm.nih.gov · clickotine.dev.clicktherapeuticsdev.com · pubmed.ncbi.nlm.nih.gov · medrxiv.org
Excerpts where Clickotine appeared in the AI's answer
Clickotine (by Click Therapeutics) : A fully digital, personalized smartphone app designed to deliver cognitive and neurobehavioral modification strategies
Clickotine is one of the best-studied digital smoking cessation interventions.
